ModernMedicine Resource Center More Topics

Hepatology Resource Center

DAA therapies can reduce overall HCV treatment costsA new study shows all-oral direct-actin antiviral agents for hepatitis C can provide both short- and long-term economic value.
HCV patient cost sharing for DAAs does not make senseInsurance arrangements for direct-acting antivirals, where hepatitis C virus patients share the burden of treatment costs, are ineffective says one researcher.
Path to eradicate HCV goes through people who inject drugsTargeting people who inject drugs may be the pathway to eradication of the hepatitis C virus (HCV), according to a recent review.
Study confirms sofosbuvir-ribavirin works against HCV genotype 2A real-world study confirms the effectiveness and safety of the all-oral combination of sofosbuvir plus ribavirin for treatment of hepatitis C virus GT2 infection.
Alcohol use high among hepatitis C virus patientsU.S. study finds those with HCV three times more likely to drink five or more drinks per day every day vs. those without HCV infections.
HCV core antigen tests a less costly diagnostic optionHCVcAg tests may cost less and improve diagnostic capacity in settings of high hepatitis C virus prevalence, according to new research.
Financial, insurance issues hinder HCV treatment study saysRemoving potential barriers to treat hepatitis C virus is yet another key component to patient access, notes lead researcher.
Baby boomers face higher mortality from HCV infectionsLead researcher says economic impact of hepatitis C virus will increase unless action is taken now.
New litigation forces states to stop restricting HCV treatmentsStates had restricted Medicaid recipients’ access to drugs, but new court rulings are changing that practice.
Primary care treats chronic HCV just as well as specialistsPCPs can “play a decisive role in eradicating” hepatitis C virus in the U.S., says lead author of new study.